poisar

Stocks · News reference

GSK Licensor Hansoh Pharma Announces Results From Second Phase III Trial For Ris-Rez In China; Study Met Its Primary Endpoint Of Progression-Free Survival In Relapsed Osteosarcoma

BenzingaJul 28, 2026, 11:19 AMBenzinga Newsdesk

Results add to a growing body of positive late-stage evidence for Ris-Rez, including recent pivotal data in advanced or relapsed small-cell lung cancerGSK is advancing development of Ris-Rez outside China across

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Jul 28, 2026, 11:19 AM
Checked
Jul 28, 2026, 11:19 AM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading